Vivoryon And MorphoSys Link To Accelerate Novel Small Molecule Checkpoint Silencing Approach

 
• By Eleanor Malone

Vivoryon CEO explains how QPCTL-targeting small molecule technology will be tested for combination with MorphoSys’s tafasitamab to enhance cancer-killing efficacy.

Security office center. Turnstile with card reader. Electronic checkpoint with a turnstile in the office center. Turnstile spinner. - Image
Technology aims to stop macrophage docking to cancer cell

More from Immuno-oncology

More from Anticancer